Luis Arzeno Tejada, MD
Endocrinology, Diabetes & Metabolism · Doylestown, PANPI 1114311347
Payments from drug & device makers
Across 104 payments — averaging $125.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Novo Nordisk$2K
- Amgen$314
- Tandem Diabetes Care, Inc.$232
- AstraZeneca$231
- Abbott$183
- plus $735 from 13 others
Across 1 payment — averaging $110.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$110
What the payments were for
- Speaking & faculty fees$7,70159%
- Travel & lodging$1,2429%
- Food & beverage$4,10631%
- Gifts$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 37 | $9,722 |
| Novo Nordisk | 14 | $1,676 |
| Amgen(2 entities) | 8 | $314 |
| Tandem Diabetes Care, Inc. | 5 | $232 |
| AstraZeneca | 2 | $231 |
| Abbott | 8 | $183 |
| Sanofi-aventis U.S. LLC | 3 | $162 |
| Insulet Corporation | 4 | $93 |
| Sequel Med Tech, LLC | 3 | $80 |
| Mannkind Corporation | 2 | $66 |
| Amarin Pharma, Inc. | 4 | $58 |
| BETA Bionics, Inc. | 4 | $53 |
| Radius Health, Inc. | 3 | $47 |
| Lilly USA, LLC | 2 | $45 |
| Neurocrine Biosciences, Inc. | 1 | $40 |
| Ascensia Diabetes Care US Inc. | 1 | $34 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$4,407
- INPEN SMART INSULIN DELIVERY SYSTEM$4,062
- FARXIGA$231
- Puritan Bennett$194
- MINIMED 770G$141
- EVENITY$125
- TOUJEO$120
- t:slim X2 Insulin Pump with Control-IQ$117
- Ozempic$113
How this compares
$13,092 in reported general payments places this provider in the 75th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 167 | $314,464 |
| MounjaroTirzepatide | 146 | $213,899 |
| JardianceEmpagliflozin | 136 | $165,544 |
| TrulicityDulaglutide | 95 | $153,908 |
| Tresiba Flextouch U-100Insulin Degludec | 87 | $59,163 |
| FarxigaDapagliflozin Propanediol | 36 | $48,273 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $40,287 |
| Novolog FlexpenInsulin Aspart | 89 | $35,851 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $32,687 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $29,849 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $25,712 |
| JanuviaSitagliptin Phosphate | 17 | $21,757 |
| TradjentaLinagliptin | 17 | $18,351 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 129 | $16,874 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 113 | $14,868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $45 | $376,521263 claims |
| Novo NordiskOzempic | $1,676 | $314,464167 claims |
| AstraZenecaFarxiga | $231 | $48,27336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Doylestown
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Vijay BahlPittsburgh$998K
- Intekhab AhmedPhiladelphia$926K
- Erin KershawPittsburgh$804K
- Geraldo SaavedraWhitehall$698K
- Arvind CavaleFeasterville Trevose$662K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.